Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections

J Am Soc Nephrol. 1991 Mar;1(9):1061-80. doi: 10.1681/ASN.V191061.

Abstract

Patients with human immunodeficiency virus infection and the acquired immunodeficiency syndrome are often treated with a variety of potentially nephrotoxic drugs. This review summarizes the renal, fluid, and electrolyte complications of drugs used to treat human immunodeficiency virus and associated opportunistic infections. The pharmacokinetics of the drugs are also briefly reviewed, and dosing guidelines for the use of these drugs in patients who have renal insufficiency or who are receiving dialysis are provided.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / adverse effects
  • Anti-Infective Agents / adverse effects*
  • Anti-Infective Agents / pharmacokinetics
  • Antifungal Agents / adverse effects
  • Antiprotozoal Agents / adverse effects
  • Antiviral Agents / adverse effects
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • Humans
  • Kidney / drug effects*
  • Kidney Diseases / chemically induced
  • Kidney Diseases / complications
  • Opportunistic Infections / complications
  • Opportunistic Infections / drug therapy

Substances

  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Antifungal Agents
  • Antiprotozoal Agents
  • Antiviral Agents